Leo Pharma will retain thrombosis business despite goal to focus on dermatology

Although Leo Pharma’s new strategy is training its sights exclusively on the dermatology area, the company has no plans to divest its second-biggest business leg dealing with thrombosis.

Leo Pharma is struggling with a growing bottom line deficit, but according to Anders Kronborg, CFO and acting CEO until April, the ship will be turned around in 2023 | Photo: Leo Pharma / PR

Leo Pharma wants to become one of the world’s biggest dermatology firms by 2030. To that end, the Danish pharmaceutical firm has laid out a strategy to streamline the business and focus efforts within the dermatology area.

Despite this, the company has no intentions of divesting its thrombosis business, which was established in 1908 and focuses on the life-threatening blood clots that form in an artery or vein.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs